Invest now
Syncom Formulations India Ltd share price
Balanced risk
- ₹13.45(-2.04%)July 17, 2026 15:29:36 PM IST
- NSE
- BSE
- Vol : 1.89 M (NSE + BSE)Last 20 day avg : 1.92 M
Syncom Formulations India Ltd is trading -2.04% lower at Rs 13.45 as compared to its last closing price. Syncom Formulations India Ltd has been trading in the price range of 13.65 & 13.30. Syncom Formulations India Ltd has given -3.93% in this year & -2.07% in the last 5 days. Syncom Formulations India Ltd has TTM P/E ratio 11.57 as compared to the sector P/E of 25.09.The company posted a net profit of 25.17 Crores in its last quarter.Listed peers of Syncom Formulations India Ltd include Sun Pharmaceutical Industries (-0.87%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (-4.72%).The Mutual Fund holding in Syncom Formulations India Ltd was at -% in . The MF holding has - from the last quarter. The FII holding in Syncom Formulations India Ltd was at 0.21% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 19 Jul 2026, 06:33 AM IST
- BetaHigh volatility2.10Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.10The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values15.39Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation0.28The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Syncom Formulations India Ltd Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,933.10 | -0.87 | 4,63,804.52 | 38.74 | 5.6 | - | - |
| Divi's Laboratories | 7,258.05 | -0.84 | 1,92,678.42 | 74.01 | 11.59 | - | - |
| Torrent Pharmaceuticals | 4,766.60 | -4.72 | 1,61,373.73 | 76.16 | 20.12 | - | - |
| Cipla | 1,418.40 | -0.77 | 1,14,584.78 | 27.78 | 3.35 | - | - |
| Zydus Lifesciences | 1,142.75 | -0.93 | 1,13,894.32 | 21.38 | 4.28 | - | - |
Syncom Formulations India Ltd Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-22 | Audited Results |
| 2026-02-12 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-08-08 | Quarterly Results & A.G.M. |
| 2025-05-19 | Audited Results |
About the company Syncom Formulations India Ltd
- IndustryBiotechnology & Drugs
- ISININE312C01025
- BSE Code524470
- NSE CodeSYNCOMF
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
Syncom Formulations India Ltd Share Price FAQs
Syncom Formulations India Ltd is trading at 13.45 as on Fri Jul 17 2026 09:59:36. This is -2.04% lower as compared to its previous closing price of 13.73.
The market capitalization of Syncom Formulations India Ltd is 1264.30 Cr as on Fri Jul 17 2026 09:59:36.
The 52 wk high for Syncom Formulations India Ltd is 19.40 whereas the 52 wk low is 10.21
Syncom Formulations India Ltd can be analyzed on the following key metrics -
- TTM P/E: 11.57
- Sector P/E: 25.09
- Dividend Yield: 0.00%
- D/E ratio: 0.00
Syncom Formulations India Ltd reported a net profit of 76.44 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Syncom Formulations India Ltd QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.